Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism by Sierra, S. (Salvador) et al.
ORIGINAL ARTICLE
Detection of cannabinoid receptors CB1 and CB2 within basal
ganglia output neurons in macaques: changes following
experimental parkinsonism
Salvador Sierra • Natasha Luquin • Alberto J. Rico • Virginia Go´mez-Bautista •
Elvira Roda • Iria G. Dopeso-Reyes • Alfonso Va´zquez • Eva Martı´nez-Pinilla •
Jose´ L. Labandeira-Garcı´a • Rafael Franco • Jose´ L. Lanciego
Received: 23 September 2013 / Accepted: 10 June 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Although type 1 cannabinoid receptors (CB1-
Rs) are expressed abundantly throughout the brain, the
presence of type 2 cannabinoid receptors (CB2Rs) in neu-
rons is still somewhat controversial. Taking advantage of
newly designed CB1R and CB2R mRNA riboprobes, we
demonstrate by PCR and in situ hybridization that tran-
scripts for both cannabinoid receptors are present within
labeled pallidothalamic-projecting neurons of control and
MPTP-treated macaques, whereas the expression is mark-
edly reduced in dyskinetic animals. Moreover, an in situ
proximity ligation assay was used to qualitatively assess
the presence of CB1Rs and CB2Rs, as well as CB1R–CB2R
heteromers within basal ganglia output neurons in all
animal groups (control, parkinsonian and dyskinetic
macaques). A marked reduction in the number of CB1Rs,
CB2Rs and CB1R–CB2R heteromers was found in dyski-
netic animals, mimicking the observed reduction in CB1R
and CB2R mRNA expression levels. The fact that chronic
levodopa treatment disrupted CB1R–CB2R heteromeric
complexes should be taken into consideration when
designing new drugs acting on cannabinoid receptor
heteromers.
Keywords GPCRs  Cannabis  Cannabinoid receptor
heteromer  Dyskinesia  Globus pallidus  MPTP
Introduction
The presence of type 1 (CB1Rs) and type 2 (CB2Rs) can-
nabinoid receptors in the CNS, particularly the basal gan-
glia, has fuelled research into their role in motor function
and dysfunction. The ubiquitously expressed CB1Rs are
found predominantly in neurons of the central and
peripheral nervous system (Freund et al. 2003). In the rat,
CB1Rs are found in the striatum, both in GABAergic
projection neurons and interneurons (Hohmann and Her-
kenham 2000; Moldrich and Wenger 2000). Initially
detected only in peripheral tissue (Munro et al. 1993;
Galiegue et al. 1995; Klein et al. 2003), the presence of
CB2Rs in the CNS has been somewhat controversial.
Present at lower expression levels than CB1Rs, differences
arising from different staining protocols and complications
with negative controls, such as CB2R-KO mice have
delayed confirmation of the presence of these receptors in
the CNS (Munro et al. 1993; Galiegue et al. 1995; Griffin
et al. 1999). Nowadays, CB2Rs have been reported in
microglia (Kearn and Hilliard 1997; Golech et al. 2004;
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Nun˜ez et al. 2004; Stella 2004; Maresz et al. 2005; Ashton
et al. 2006) and neurons (Skaper et al. 1996; Stander et al.
2005; Van Sickle et al. 2005; Wotherspoon et al. 2005;
Beltramo et al. 2006; Onaivi et al. 2006; Brusco et al.
2008a, b; den Boon et al. 2012). Within the basal ganglia,
CB2Rs are expressed in neurons from both segments of the
globus pallidus (GPe and GPi) of Macaca fascicularis
(Lanciego et al. 2011) and in the substantia nigra pars
reticulata (SNr) of the rat (Gong et al. 2006).
The expression of cannabinoid receptors in the basal
ganglia has important implications for motor dysfunction,
such as Parkinson’s disease (PD). Data suggest that CB1R
expression levels in the striatum are upregulated in rodent
and primate models of PD (Mailleux and Vanderhaeghen
1993; Romero et al. 2000; Lastres-Becker et al. 2001) and
in PD patients (Lastres-Becker et al. 2001). Activation of
CB1Rs inhibits neurotransmitter release through endo-
cannabinoid retrograde signaling, capable of reducing
neuronal signaling (Shen et al. 1996). In basal ganglia
output nuclei (GPi and SNr), CB1R activation reduces
both GABA and glutamate release from striatal and
subthalamic inputs, respectively (San˜udo-Pen˜a et al.
1999). Intracellular CB2Rs have also been suggested to
reduce neuronal firing rate (den Boon et al. 2012).
Despite the interest related to endocannabinoid-based
neuroregulation in the basal ganglia, neuronal CB1R and
CB2R expression has not been properly characterized
within GPi and SNr.
The present study was conducted to establish whether
CB1R and CB2R transcripts are present in pallidothalamic
projection neurons. Given that mRNA for the two receptors
was present in the same neurons, and an in situ proximity
ligation assay (PLA) detected the localization of CB1Rs,
CB2Rs and CB1R–CB2R heteromers in the cell somata of
projection neurons. Experiments performed in control,
parkinsonian and dyskinetic macaques demonstrated that
CB1Rs, CB2Rs and CB1R–CB2R heteromer levels were
similar in naı¨ve and parkinsonian animals, and markedly
reduced in dyskinetic macaques.
Materials and methods
A total of eight naı¨ve adult male Macaca fascicularis pri-
mates (body weight 3.8–4.5 kg) were used in this study.
Animal handling was conducted in accordance with the
European Council Directive 86/609/EEC, as well as in
agreement with the Society for Neuroscience Policy on the
Use of Animals in Neuroscience Research. The experi-
mental design was approved by the Ethical Committee for
Animal Testing of the University of Navarra (ref: 009-12).
All animals were captive-bred and supplied by Harlan
Laboratories.
MPTP treatment and levodopa
The dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP; Sigma) was administered
intravenously to four macaques at a concentration of
0.2 mg/kg (injected once weekly) until animals reached a
stable parkinsonian syndrome. The severity of MPTP-
induced parkinsonism was evaluated by two independent
blind observers using clinical rating scales (Kurlan et al.
1991) where the highest score was 29. All MPTP-treated
macaques reached a stable score between 21 and 25 points
that was maintained over a period of 2 months of MPTP
washout. Two monkeys were selected to receive daily oral
treatment with levodopa and benserazide (25 mg/kg of
Madopar, Roche, France). These monkeys developed a
mild dyskinetic syndrome by the end of the first month of
treatment, then displaying overt dyskinetic symptoms
1 month later and remained stable until the CTB retrograde
tracer injection. The extent of the MPTP-induced dopa-
minergic depletion was confirmed by immunohistochemi-
cal detection of tyrosine hydroxylase, as shown in Rico
et al. (2010) and Conte-Perales et al. (2011).
Stereotaxic surgery, perfusion and tissue processing
Surgical anesthesia was induced by intramuscular injection
of ketamine (5 mg/kg) and midazolam (5 mg/kg), resulting
in deep anesthesia over a period of 2–3 h. Local anesthesia
was implemented just before surgery by means of a 10 %
solution of lidocaine. Analgesia was achieved with a single
intramuscular injection of flunixin meglumine (Finadyne,
5 mg/kg) delivered at the end of the surgical procedure and
repeated 24 and 48 h post surgery. A similar schedule was
followed for antibiotic delivery of ampicillin (0.5 ml/day).
After surgery, animals were kept under constant monitoring
in single cages with ad libitum access to food and water.
Stereotaxic coordinates for ventral anterior and ventral
lateral thalamic nuclei (VA/VL) were taken from the atlas
by Lanciego and Va´zquez (2012). During surgery, target
selection was assisted by ventriculography. Selected
coordinates for targeting VA/VL with cholera toxin B
subunit (CTB) were 4.5 mm caudal to the anterior com-
missure (ac), 4 mm lateral to the midline and 2 mm dorsal
to the intercommissural plane (ac–pc line).
Six monkeys (2 control, 2 parkinsonian and 2 dyskinetic
monkeys) received a single pressure injection of 5 ll of
unconjugated cholera toxin subunit B (CTB, List Biologi-
cal Laboratories, Campbell, CA) through a Hamilton syr-
inge (5 mg/ml in 0.01 M phosphate buffer, pH 7.5) in the
VA/VL nuclei. Tracer delivery was accomplished in pulses
of 1 ll every 2 min and, once completed, the microsyringe
was left in place for 15 min before withdrawal to minimize
tracer uptake through the injection tract.
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After 2 weeks of postsurgery, animals were anesthetized
with an overdose of 10 % chloral hydrate and perfused
transcardially (for dyskinetic monkeys, terminal anesthesia
was administered at the time point at which they showed
overt, peak-of-dose dyskinesias). The perfusates consisted
of a saline Ringer solution followed by 3,000 ml of a fix-
ative solution containing 4 % paraformaldehyde and 0.1 %
glutaraldehyde in 0.125 M phosphate buffer (PB), pH 7.4.
Perfusion was continued with 1,000 ml of a cryoprotectant
solution containing 10 % glycerin and 1 % dimethyl-
sulphoxide (DMSO) in 0.125 M PB, pH 7.4. Once perfu-
sion was completed, the skull was opened, the brain
removed, and stored for 48 h in a cryoprotectant solution
containing 20 % of glycerin and 2 % DMSO in
0.125 M PB, pH 7.4. All solutions used for fixation and
cryoprotection were treated with 0.1 % diethylpyrocar-
bonate (DEPC) and autoclaved prior to their use. Finally,
frozen serial sagittal sections (40 lm-thick) were obtained
on a sliding microtome and collected in 0.125 M PB, pH
7.4, as 15 series of adjacent sections. The series were used
for: (1) immunohistochemical detection of tyrosine
hydroxylase, (2) immunohistochemical detection of trans-
ported CTB, later counterstained with Nissl stain, (3) single
colorimetric in situ hybridization to detect CB1R mRNA,
(4) single colorimetric in situ hybridization to detect CB2R
mRNA, (5) immunofluorescent detection of transported
CTB combined with dual fluorescent in situ hybridization
using antisense riboprobes for CB1R and CB2R, (6)
immunofluorescent detection of CTB combined with in situ
proximity ligation assay (PLA) to detect CB1Rs, (7)
immunofluorescent detection of CTB combined with PLA
to detect CB2Rs and (8) immunofluorescent detection of
transported CTB combined with PLA to detect CB1R–
CB2R heteromers. Some additional sections were used for
the ultrastructural detection of CB1R–CB2R heteromers, as
indicated below. The remaining series of sections were
stored at -80 C for further histological processing, if
needed.
Detection of transported CTB
Immunohistochemical detection of transported CTB was
carried out on sagittal sections throughout the entire
mediolateral extent of the left brain hemisphere. Sections
were incubated with a primary antibody against CTB raised
in rabbit (1:2000; overnight at 4 C; GenWay, San Diego,
CA, USA) followed by a biotinylated donkey antirabbit
IgG (1:200; 2 h at room temperature—RT; Jackson
Immunoresearch). Sections were incubated in HRP-conju-
gated streptavidin (1:5000; 90 min at RT: Sigma) and
finally visualized in brown with DAB (Sigma). Sections
were mounted on gelatin-coated glass slides, dried at RT
and subsequently counterstained with thionin to accurately
delineate the boundaries of the brain structures showing
CTB labeling. Once the Nissl stain was completed, sections
were coverslipped with Entellan (Merck).
Polymerase chain reaction
For PCR amplification, fresh tissue samples (unfixed) from
two control naı¨ve primates available in our monkey brain
bank were used. Briefly, a brain block containing the stri-
atum, GPe and GPi was frozen rapidly in isopentane,
cooled with liquid nitrogen and coronal sections
(20 lm thick) were obtained using a cryostat. The sections
were mounted on dedicated plastic-coated slides (Leica
Microsystems) for laser-guided capture microdissection
(LCM). Under the LCM microscope (Leica), the bound-
aries of the striatum, GPe and GPi were delineated and
dissected separately from the tissue using the laser beam.
The tissue samples obtained from these regions were col-
lected in separate 0.5 ml Eppendorf vials containing lysis
buffer for RNA extraction. Total RNA was extracted using
the Absolutely RNA Nanoprep kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s instructions and
including the optional DNase I digestion step. The RNA,
eluted in a final volume of 10 ll, was used entirely for
reverse transcription. The cDNA template was obtained by
adding 1 ll 10 mM dNTP mix, 1 ll 0.1 M DTT, 50 ng
hexamers, 1 ll RNase inhibitor (40 U/ll; Promega, Mad-
ison, WI, USA), 4 ll 59 first-stand buffer, 2 ll sterile
water and 1 ll SuperScript III reverse transcriptase (200 U/
ll; Invitrogen) in a final volume of 20 ll and incubated at
50 C for 60 min. Subsequently, the reaction was inacti-
vated by heating at 70 C for 15 min.
PCRs were carried out in a final volume of 50 ll con-
taining 25 mM of each primer, 0.5 ll of Taq DNA poly-
merase (Bioline), 5 ll 109 Taq DNA polymerase PCR
buffer, 1.5 ll MgCl2, 2 ll dNTP and 8 ll per reaction of
pure cDNA for amplification in the case of CB1R and
CB2R and 2 ll of cDNA in the case of the control gene
GAPDH. After 94 C for 5 min, the thermocycling
parameters were as follows: 35 cycles of 94 C for 30 s,
58 C for 30 s and 72 C for 1 min. The extension reaction
was carried out for 10 min at 72 C, and reaction products
were stored at 4 C. The primers used in PCR were: for-
ward CATCCAGTGTGGGGAGAACT and reverse TAT
GGTCCACATCAGGCAAA for CB1R (product size
445 bp), forward CATCACTGCCTGGCTCACT and
reverse AGCATAGTCCTCGGTCCTCA for CB2R (prod-
uct size 662 bp) and forward CATCCTGCACCACCAA
CTGCTTAG and reverse GCCTGCTTCACCACCTTCT
TGATG for GAPDH (product size 343 bp). The PCR
products were analyzed by electrophoresis on a 1 % aga-
rose gel containing SYBR Safe DNA gel stain (Invitrogen)
under ultraviolet light.
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Synthesis of sense and antisense riboprobes for CB1R
and CB2R mRNA
Total RNA was isolated from a Macaca fascicularis using
the Trizol reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA). Spleen tissue samples were disrupted in 1 ml
Trizol reagent using a homogenizer. After 5 min incuba-
tion at RT, 0.2 ml of chloroform was added and mixed
vigorously; the sample was then centrifuged at 12,000g for
15 min at 4 C. Following centrifugation, the supernatant
was placed in a new tube, and 0.5 ml isopropanol was
added followed by incubation for 10 min at RT. The RNA
pellet was obtained by centrifugation at 12,000g for 10 min
at 4 C. The pellet was washed in 1 ml 75 % ethanol and,
after vaporization of ethanol, dissolved in 30 ml DEPC-
treated water. Absorbance at 260 nm was determined
to quantify the amount of total RNA, which was stored at
-80 C.
First-strand cDNA was synthesized from the total RNA
extracted and 0.5 mg of total RNA was subjected to PCR
by adding Superscript III reverse transcriptase (Invitrogen)
(1 ll, 200 U/ll), oligo-(dT) (1 ml, 50 mM), buffer (4 ll,
59 First-Strand Buffer: 200 mM Tris–HCl, 500 mM KCl,
50 mM MgCl2), dithiothreitol (1 ll, 0.1 M) and mixed
dNTPs (1 ll, 10 mM; Invitrogen) adding DEPC-treated
water to make up a final volume of 20 ll.
Template cDNA sequences were obtained from Gen-
Bank (http://www.ncbi.nlm.nih.gov/). Oligonucleotide
primers were designed using Primer3Input v.0.4.0 software
(http://www.frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi). Primers designed for CB1R and CB2R were the
abovementioned primers. PCR was performed with Pfx
polymerase (Invitrogen) and 35 cycles of amplification
(denaturation at 95 C for 1 min, annealing at 58 C for 30 s,
extension at 68 C for 1 min) and a final extension at 68 C
for 10 min. The PCR products were analyzed by electro-
phoresis on a 0.8 % agarose gel containing SYBR Safe DNA
gel stain (Invitrogen) under ultraviolet light and purified
using a QIAquick Gel Extraction kit (QIAGEN GmbH).
The PCR product was later inserted into the plasmid
vector (pCR-Blunt II-TOPO; Invitrogen) and used to trans-
form competent E. coli cells (Invitrogen). The product
extracted using the Miniprep kit (Qiagen) was then
sequenced (3130XL Genetic Analyzer, Applied Biosys-
tems). The computer-assisted homology searches (see http://
www.blast.ncbi.nlm.nih.gov/Blast.cgi) conducted showed
that the CB1R cDNA sequence had 100 % homology with
human CB1R transcript variant 1 (accession number
NM_016083) and variant 2 (accession number
NM_033181), and 99 % homology with Macaca mulatta
CB1R (accession number NM_001032825). CB2R cDNA
sequence had 94 % homology with human CB2R
(NM_001841) and 99 % homology with Macaca mulatta
CB2R (accession number XM_001105018) sequences,
without any significant homology with CB1R for the dif-
ferent species, and the same holds true when comparing the
homologies of CB1R cDNA sequence with CB2R. Further-
more, the designed probe recognizes both CB2AR and
CB2BR isoforms which have been recently reported (Liu
et al. 2009).
Sense and antisense riboprobes for Macaca fascicularis
CB1Rs or CB2Rs were transcribed from the Zero Blunt
TOPO PCR cloning kit plasmid. The plasmid was linear-
ized and the sense or antisense probes were transcribed
with the appropriate RNA polymerases (Boehringer
Mannheim, Germany). The transcription mixture included
1 lg template plasmid, 1 mM each of ATP, CTP and GTP,
0.7 mM UTP and 0.3 mM digoxigenin-UTP, 10 mM DTT,
50 U RNase inhibitor and 1 U of either T7 or SP6 RNA
polymerase in a volume of 50 ll. After 2 h at 37 C, the
template plasmid was digested with 2 U RNase-free
DNAse for 30 min at 37 C. The sense and antisense
riboprobes were then precipitated by the addition of 100 ll
of 4 M ammonium acetate and 500 ll of ethanol and
finally recovered by centrifugation at 4 C for 30 min. The
quality of the synthesis was monitored by dot blot.
Dual fluorescent in situ hybridization combined
with immunofluorescent detection of transported CTB
Dual fluorescent in situ hybridization procedures were
carried out on free-floating sections that were incubated
twice in 0.1 % DEPC in PB for 15 min and pre-equili-
brated for 10 min in 59 SSC (0.75 M NaCl, 0.0075 M Na–
citrate). Sections were then incubated at 58 C for 2 h in a
hybridization solution containing 50 % deionized form-
amide, 59 SSC and 40 lg/ll of denatured salmon DNA in
H2O-DEPC. A mixture of the biotin-labeled CB2R ribop-
robe and digoxigenin-labeled CB1R riboprobe were used,
denatured for 5 min at 77 C and then added to the
hybridization mix at 400 ng/ml. Sections were hybridized
in this solution overnight at 58 C. Posthybridization
washes were carried out in 29 SSC at RT for 15 min, 29
SSC for 30 min at 65 C and then in 0.19 SSC for 30 min
at 65 C.
The biotin-labeled probe was the first to be visualized
after immersing the sections for 15 min in 3 % H2O2 to
inactivate the endogenous peroxidase activity. After sev-
eral rinses in TNT buffer (0.1 M Tris–HCl, pH 7.5, 0.15 M
NaCl, 0.05 % Tween 20) the sections were equilibrated for
30 min in TNB (0.1 M Tris–HCl, pH 7.5, 0.15 M NaCl,
0.5 % blocking reagent, Perkin Elmer), then incubated with
streptavidin-conjugated horseradish peroxidase (1:50, Per-
kin Elmer) in TNB buffer for 30 min at RT. After several
washes with TNT buffer, the sections were incubated for
10 min in biotinyl tyramide (1:50 in amplification diluent;
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Perkin Elmer). The fluorescent labeling was then visualized
using Alexa-633 conjugated streptavidin (1:100; Molecular
Probes).
The CB1R mRNA transcript, detected with a digoxi-
genin-labeled riboprobe, was visualized immediately fol-
lowing the biotin-labeled probe. Sections were briefly
rinsed with TN buffer (0.1 M Tris–HCl, pH 7.5, 0.15 M
NaCl) and incubated for 90 min at RT with an anti-
digoxigenin antibody raised in sheep (1:1200; Roche
Diagnostics). After several rinses in TNT buffer, sections
were washed three times for 5 min with TNM buffer
(0.1 M Tris–HCl, pH 8, 1 M NaCl, 100 mM MgCl2) at RT
and transcripts were finally visualized using the HNPP
fluorescence detection kit (Roche Diagnostics), to be
viewed with the red channel.
Immediately following the double fluorescent in situ
hybridization assay, fluorescent immunodetection of
transported CTB was carried out. As outlined above, a
rabbit anti-CTB primary antibody was used, followed by a
secondary donkey antirabbit Alexa488-conjugated anti-
body (1:200, 2 h; Molecular Probes). Sections were then
mounted on gelatin-coated glass slides, dried in the dark,
dehydrated rapidly in toluene and coverslipped with DPX
(VWR International).
Fusion proteins and expression vectors
Human cDNA for CB1, CB2 and dopamine D4.2 receptors
cloned in pcDNA3.1 were amplified without their stop
codons using sense and antisense primers harboring either
unique EcoRI and BamH1 sites (CB1R, CB2R) or Xho1 and
EcoR1 (D4.2R). The fragments were then subcloned to be
in-frame with Rluc into the EcoRI and BamH1 (CB1R)
restriction site of an Rluc-expressing vector (pRluc-N1,
PerkinElmer, Wellesley, MA), or into the BamH1 and
EcoRI (CB2R) or Xho1 and EcoR1 (D4.2R) restriction site
of an EYFP expressing vector (EYFP-N1; enhanced yellow
variant of GFP; Clontech, Heidelberg, Germany), to create
plasmids that express CB1R, CB2R or D4.2R fused to Rluc
or YFP on the C-terminal end of the receptor (CB1R–Rluc,
CB2R-YFP or D4.2R-YFP). The expression of constructs
was tested using confocal microscopy and receptor func-
tionality using the ERK1/2 activation pathway.
Cell line cultures and transfection
Human embryonic kidney 293T (HEK-293T) cells were
grown in DMEM supplemented with 2 mM L-glutamine,
1 mM sodium pyruvate, 100 units/ml penicillin/strepto-
mycin and 5 % (v/v) heat-inactivated fetal bovine serum
(FBS) (all supplements were from Invitrogen, Paisley,
Scotland, UK). Cells were maintained at 37 C in a
humidified atmosphere of 5 % CO2, and were passaged
when they were 80–90 % confluent, i.e. approximately
twice a week.
HEK-293T cells were transiently transfected with the
corresponding fusion protein cDNA by the ramified PEI
(PolyEthylenImine, Sigma, St. Louis, MO, USA) method.
Cells were incubated (4 h) with the corresponding cDNA
together with ramified PEI (5 ml of 10 mM PEI for each mg
cDNA) and 150 mM NaCl in a serum-starved medium. After
4 h, the medium was changed to a fresh complete culture
medium. After 48 h of transfection, cells were washed twice
in quick succession in Hanks’ balanced salt solution HBSS
(137 mMNaCl, 5 mMKCl, 0.34 mM Na2HPO4 9 12H2O,
0.44 mM KH2PO4, 1.26 mM CaCl2 9 2H2O, 0.4 mM
MgSO4 9 7H2O, 0.5 mM MgCl2, 10 mM HEPES, pH 7.4)
supplemented with 0.1 % glucose (w/v), detached by gently
pipetting and resuspended in the same buffer. To control the
cell number, sample protein concentration was determined
using a Bradford assay kit (Bio-Rad, Munich, Germany)
using bovine serum albumin dilutions as standards. HEK-
293T cell suspension (20 lg of protein) was distributed into
96-well microplates; black plates with a transparent bottom
(Porvair, Leatherhead, UK) were used for fluorescence
determinations, whereas white opaque plates (Porvair,
Leatherhead, UK) were used for bioluminescence resonance
energy transfer (BRET) experiments.
BRET assays
HEK-293T cells were transiently co-transfected with the
indicated amounts of plasmid cDNAs corresponding to the
indicated fusion proteins (see Fig. 6). To quantify receptor-
fluorescence expression, cells (20 lg protein) were dis-
tributed in 96-well microplates (black plates with a trans-
parent bottom; Porvair, Leatherhead, UK) and fluorescence
was read using a Mithras LB 940 (Berthold, Bad Wildbad,
Germany) equipped with a high-energy xenon flash lamp,
using an excitation filter of 485 nm. Receptor-fluorescence
expression was determined as fluorescence of the sample
minus the fluorescence of cells expressing protein-Rluc
alone. For BRET measurements, the equivalent of 20 lg of
cell suspension were distributed in 96-well microplates
(white plates; Porvair, Leatherhead, UK) and 5 lM coel-
enterazine H (PJK GMBH, Germany) was added. After
1 min of adding coelenterazine H, readings were collected
using a Mithras LB 940 (Berthold, Bad Wildbad, Germany)
that allows the integration of the signals detected in the
short wavelength filter at 485 nm (440–500 nm) and the
long wavelength filter at 530 nm (510–590 nm). To quan-
tify the receptor-Rluc expression luminescence readings
were performed after 10 min of adding 5 lM coelenter-
azine H. Cells expressing BRET donors alone were used to
determine background. The net BRET is defined as [(long-
wavelength emission)/(short-wavelength emission)]-Cf
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where Cf corresponds to [(long-wavelength emission)/
(short-wavelength emission)] for the Rluc construct
expressed alone in the same experiment. BRET curves were
fitted using a nonlinear regression equation, assuming a
single phase with GraphPad Prism software (San Diego,
CA, USA). BRET is expressed as mili BRET units (mBU:
1,000 9 net BRET).
In situ proximity ligation assay (PLA)
The PLA technique was carried out both on cell cultures as
well as on histological sections. Briefly, 3 different HEK-
293T cell lines transiently expressing CB1R, CB2R or both
receptors were fixed in 4 % paraformaldehyde for 15 min
and washed with PBS containing 20 mM glycine to quench
the aldehyde groups. The presence/absence of receptor–
receptor molecular interaction in these samples was
detected using the Duolink II in situ PLA detection kit
(Olink Bioscience, Uppsala, Sweden). To detect CB1R–
CB2R heteromers, the rabbit anti-CB1R antibody (Thermo
Scientific, Rockford, USA) was linked to a plus PLA probe
and the rabbit anti-CB2R antibody (Cayman Chemical,
Ann Arbor, USA) was linked to a minus PLA probe fol-
lowing the manufacturer’s instructions. After incubation
for 1 h at 37 C with the blocking solution in a preheated
humidity chamber, cell cultures were incubated overnight
with these PLA probe-linked antibodies (final concentra-
tion of 65 lg/ml) at 4 C. Next, samples were immersed
for 1 h in a 1:400 solution of TOPRO-3 (Molecular Probes-
Invitrogen) for nuclear staining. After washing with buffer
A at RT, the cells were incubated with the ligation solution
for 1 h at 37 C in a humidity chamber. Following washes
with buffer A, samples were incubated with the amplifi-
cation solution for 100 min at 37 C in humidity chamber
and then washed with buffer B, followed by another wash
with buffer B 9 0.01. Samples were mounted using an
aqueous mounting medium. Cell lines transfected only with
either CB1R or CB2R were used as appropriate negative
control assays for the PLA technique to ensure that there
was a lack of nonspecific labeling.
Tissue sections containing the GPi were used for the
immunofluorescent visualization of transported CTB fol-
lowed by a PLA protocol to detect CB1Rs, CB2Rs, and
CB1R–CB2R heteromers. The PLA technique has been
successfully employed to detect G-protein-coupled recep-
tor heteromers in the striatum (Trifilieff et al. 2011) as well
as in the globus pallidus (Callen et al. 2012). The method is
based on the use of two primary antibodies (against each
target receptor) covalently coupled to a pair of affinity
oligonucleotide probes (a plus and minus probe). Only
when the target proteins are in close proximity (\17 nm)
do the probes ligate (Callen et al. 2012) and form templates
for rolling circle amplification (amplifying the DNA
molecule 1,000-fold) (So¨derberg et al. 2008; Trifilieff et al.
2011). Hybridization of complementary fluorescently
labeled oligonucleotides with the amplified DNA is then
seen as a red dot with fluorescent microscopy, representing
a single protein–protein interaction.
The receptor–receptor molecular interaction in these
samples was detected using the Duolink II in situ PLA
detection kit (Olink Bioscience). To detect CB1R–CB2R
heteromers in tissue sections, the rabbit anti-CB1R anti-
body (Thermo Scientific) was linked to a plus PLA probe
and the rabbit anti-CB2R antibody (Cayman Chemical) was
linked to a minus PLA probe following the manufacturer’s
instructions. After incubation for 1 h at 37 C with the
blocking solution in a preheated humidity chamber, tissue
sections were incubated overnight with these PLA probe-
linked antibodies (final concentration of 65 lg/ml) at 4 C.
After washing with buffer A at RT, sections were incubated
with the ligation solution for 1 h at 37 C in a humidity
chamber. Following washes with buffer A, sections were
incubated with the amplification solution for 100 min at
37 C in a humidity chamber. Sections were then washed
with buffer B, followed by a wash with buffer B9 0.01.
Samples were mounted using an aqueous mounting med-
ium. Appropriate negative control assays were carried out
to ensure that there was a lack of nonspecific labeling and
amplification. In addition to using the PLA technique for
detecting CB1R–CB2R heteromers, we have modified the
original protocol according to the suggestions issued by the
supplier in order to further use this technique to detect
single cannabinoid receptors. Accordingly, we have used
either a rabbit anti-CB1R (Thermo Scientific) or a rabbit
anti-CB2R (Cayman Chemical) followed by two secondary
donkey-antirabbit antibodies, one linked to a plus PLA
probe, the other linked to a minus PLA probe.
Confocal visualization settings and densitometries
Stained samples (in situ hybridization and PLA) were
inspected under a Zeiss 510 Meta confocal laser-scanning
microscope (CLSM). To ensure appropriate visualization
of the labeled elements and to avoid false positive results,
the emission from the argon laser at 488 nm was filtered
through a band pass filter of 505–530 nm and color-coded
in green. The emission following excitation with the
helium laser at 543 nm was filtered through a band-pass
filter of 560–615 nm and color coded in light blue. Finally,
a long-pass filter of 650 nm was used to visualize the
emission from the helium laser at 633 nm and color coded
in red. A similar band-pass filter setup was used for the
visualization of either CTB-labeled neuronal structures
showing PLA labeling. Since in these cases, there was no
need to use the infrared laser, the observed emission from
the helium laser at 543 nm was color-coded in red.
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Electron microscopy
Ultrastructural detection of CB1R–CB2R heteromers was
carried out using the PLA technique followed by immu-
nogold labeling and silver enhancement. Proximity probes
consisted of affinity-purified antibodies modified by cova-
lent attachment of 50 end of various oligonucleotides to
each primary antibody. To create our PLA probes we
conjugate a rabbit anti-CB1R with a PLUS oligonucleotide
(Sigma, Duolink In Situ Probemaker PLUS catalogue
number DUO92009) and a rabbit anti-CB2R with a MINUS
oligonucleotide (Sigma, Duolink In Situ Probemaker
MINUS catalogue number DUO92010) following the
manufacturer’s instructions.
Free-floating sections were incubated 15 min in a 0.1 %
sodium borohydride solution, after rinsing in PB and buffer
A (Wash buffer A catalogue number DUO82047, Sigma)
were incubated for 1 h at 37 C with the blocking solution
(Sigma, Duolink In Situ Probemaker PLUS catalogue
number DUO92009), followed by overnight incubation with
the PLA probe-linked antibodies described above (final
concentration of 60 lg/ml) at 4 C. The presence/absence of
receptor–receptor molecular interaction in these samples
was detected using the Duolink II in situ PLA detection kit
(Sigma, Duolink In Situ Detection Reagents Brightfield,
catalogue number DUO92012). Following the detection
protocol described by the manufacturer, sections were
washed with buffer A at room temperature and incubated
with the ligation solution for 1 h at 37 C. Following washes
with buffer A, samples were incubated with the amplification
solution for 100 min at 37 C. Afterwards sections were
rinsed in buffer A and incubated the detection solution,
consisting of horseradish peroxidase (HRP) labeled oligo-
nucleotides for 1 h at room temperature. After rinsing in
buffer A, free-floating sections were incubated in blocking
solution containing 3 % NGS, 0.005 % triton X-100, 1 %
BSA, 0.05 M glycine and 1 % w/v nonfat dry milk in PBS for
1 h. Afterwards sections were incubated overnight at 4 C
with goat antihorseradish peroxidase 4 nm colloidal gold
(Jackson Immunoresearch, catalogue number 123-185-021)
1:100 diluted in a solution of 3 % NGS, 0.005 % triton
X-100, 1 % BSA and 1 % w/v nonfat dry milk in PBS.
Sections were washed with PB 0.1 M and postfixed in a
2.5 % glutaraldehyde solution for 2 h. Washes with PB
0.1 M were followed by washes with distilled water and
finally sections were incubate in a silver enhancement
solution (Aurion R-Gent SE-EM Silver Enhancement
Reagents, catalogue number 500.044) for 90 min at room
temperature. After rinsing with distilled water sections
were postfixed in 1 % Osmium solution in distilled water
for 20 min. Rinse in 0.1 M PB and dehydrate 2 9 10 min
in 50 % ethanol, 1 9 45 min in a 1 % uranyl acetate
solution in 70 % ethanol followed by 90 %, 100 % ethanol
and propylene oxide for 2 9 10 min each. Incubate
sequentially with 3:1, 1:1, 1:3 propylene oxide and Embed-
812 mix, 30 min each and finally incubate overnight at
room temperature in straight Embed-812. Sections
including GPe and GPi were flat-embedded and baked in
60 C oven for 72 h.
Following polymerization, the region of interest was
checked employing low-magnification lens; using the point
of a sharp scalpel the areas of interest (GPe and GPi) were
cut out. The cut fragments were glued onto resin specimen
blocks, previously polymerized, and stored at 4 C. Using a
Leica Ultracut R ultramicrotome thin sections of silver-
gold color were collected on carbon-coated grids (150
mesh) and store until use.
Grids were examined using a digital Zeiss Libra 120
energy filter transmission microscope (EFTEM) operated at
80,000 kV.
Statistical analyses
The intensity of CB1R and CB2R mRNA expression in
CTB-labeled neurons was measured with bi-dimensional
densitometry software available for the Zeiss 510 Meta
CLSM. Briefly, a flat projection of each confocal stack
obtained with the 940 oil-immersion lens was generated
for each channel showing CTB, CB1R or CB2R mRNA
labeling. The number of pixels within a given region of
interest (ROI) were counted at the single-cell level and
normalized against the background staining. For each
animal, the densitometry analysis was performed on
approximately 80 CTB-labeled neurons. The only neurons
considered as appropriate ROIs for densitometric analysis
were those in which the nucleus was clearly visible. The
means and standard deviations were then calculated and
compared for each variable (CB1R mRNA and CB2R
mRNA). The values across the two monkeys in each group
were homogeneous, therefore considered as ‘statistically
equivalent’ and thus the values were analyzed together. We
assessed the statistical significance of the differences
between the experimental groups using ANOVA tests
followed by post hoc tests for multiple comparisons. All
p values reported here are two-tailed and statistical sig-
nificance was defined a priori at p = 0.05. Data analyses
were performed using SPSS 15.0 (SPSS, Inc.).
Results
Expression of CB1R and CB2R mRNA transcripts
in the GPi nucleus
The presence of CB1R and CB2R mRNA transcripts in GPi
was confirmed by PCR (Fig. 1) in samples from two naı¨ve
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animals. Sense and antisense riboprobes for CB1R and
CB2R mRNAs were generated and tested to confirm the
presence of specific hybridization signals. Appropriate
levels of gene expression were detected using antisense
riboprobes, whereas hybridization with the riboprobe in the
sense direction resulted in a complete lack of stain (Fig. 2).
Co-expression of CB1R and CB2R mRNA
in pallidothalamic projection neurons
Pallidothalamic-projecting neurons of naı¨ve animals were
unequivocally identified following the delivery of large
deposits of CTB in the VA/VL thalamic nuclei in six pri-
mates (2 control, 2 parkinsonian and 2 dyskinetic). Tracer
leakage through the needle tract was not observed in any of
the CTB-injected monkeys (an example of an injection site
is illustrated in Fig. 3). In all cases, following the delivery
of CTB in the VA/VL, a large number of retrogradely
labeled neurons was found in the ipsilateral GPi nucleus
(Fig. 3) and substantia nigra pars reticulata, as well as in
the pedunculopontine nucleus, bilaterally. A more moder-
ate number of CTB-labeled neurons was observed in the
ipsilateral subthalamic nucleus (Rico et al. 2010) and in the
contralateral deep cerebellar nuclei.
The combination of dual fluorescent in situ hybridiza-
tion together with the immunofluorescent detection of CTB
enabled the unequivocal demonstration that all palli-
dothalamic-projecting neurons co-expressed both CB1R
and CB2R mRNA, as seen in control, parkinsonian and
dyskinetic monkeys (Fig. 4). Only a minimal fraction of
CTB-labeled neurons (less than 1 %) did not show CB1R
and CB2R mRNA transcripts, whereas a few CTB-
Fig. 1 Detection by PCR amplification of CB1R and CB2R mRNA
transcripts in the GPi. GAPDH mRNA was used as a positive control
Fig. 2 Detection of CB1R and CB2R mRNA using in situ hybrid-
ization. Using colorimetric in situ hybridization in a naı¨ve primate,
CB1R and CB2R mRNA (panels a, b and e, f, respectively) were
detected in the GPi nucleus. The sense probes did not provide specific
labeling of CB1R or CB2R mRNA (panels c, d and g, h, respectively).
Even at low magnification, a lack of stain when using sense probes for
CB1R and CB2R mRNA (panels c and g) was observed in the
hippocampal formation, which was stained specifically when using
antisense probes for both transcripts (a and e). Scale bar is 3,000 lm
for panels a, c, e and g and 150 lm for insets b, d, f and h. ac anterior
commissure, GPe external division of the globus pallidus, GPi
internal division of the globus pallidus, hipp hippocampal formation,
ot optic tract, SN substantia nigra, STN subthalamic nucleus
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Fig. 3 Retrograde CTB labeling of pallidothalamic-projecting neu-
rons. CTB deposits were placed at the level of VA/VL thalamic nuclei
in control, parkinsonian and dyskinetic monkeys. Following CTB
injection in VA/VL nuclei (a), a large number of retrogradely labeled
neurons were found throughout all territories of the GPi nucleus (b).
Panel c shows an inset taken from panel B at a higher magnification.
Scale bar is 3,000 lm in panel a, 1,000 lm in panel b, and 100 lm in
panel c. ac anterior commissure, GPe external division of the globus
pallidus, GPi internal division of the globus pallidus, ic internal
capsule, SN substantia nigra, STN subthalamic nucleus, ot optic tract
Fig. 4 Co-expression of CB1R and CB2R mRNA in pallidothalamic
neurons in control, parkinsonian and dyskinetic monkeys. Immuno-
fluorescent detection of transported CTB combined with dual
fluorescent in situ hybridization for the detection of CB1R and
CB2R mRNA. All pallidothalamic projecting neurons (green channel)
co-expressed CB1R (red channel) and CB2R (blue channel) mRNA.
CB2R mRNA was expressed at lower levels than CB1R mRNA across
all experimental conditions. Most importantly, there was a marked
reduction in expression levels for both CB1R and CB2R mRNA
transcripts in the dyskinetic state. Scale bar is 50 lm for all panels
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unlabeled neurons displayed CB1R and CB2R mRNA
co-expression.
Quantification of CB1R and CB2R mRNA expression
levels
CB1R mRNA levels were consistently higher than CB2R
mRNA levels in all three experimental groups (Fig. 5).
Variance analysis showed intra-group homogeneity. Given
that the variance value for either CB1R or CB2R was not
homogeneous across the three experimental groups, the
Tamhane’s post hoc test was used for intergroup compari-
sons. Using this test to compare CB1R mRNA values, the
mean differences between control and MPTP (p = 0.021),
control and dyskinetic (p \ 0.001) and MPTP and dyski-
netic groups (p \ 0.001) were statistically significant. The
mean differences of CB2R values between groups were
statistically significant between control and dyskinetic
(p \ 0.001) and between MPTP and dyskinetic groups
(p \ 0.001); however no difference that was statistically
significant was found between control and MPTP monkeys
(p = 0.946). Dyskinetic monkeys displayed a marked
downregulation of both CB1R and CB2R mRNA expression
with respect to the levels found both in control and MPTP-
treated monkeys (Fig. 5).
Presence of CB1R–CB2R heteromers in transfected
cells: BRET analysis
Evidence showing that CB1Rs and CB2Rs form heteromers
in HEK-293T transfected cells was reported recently (Cal-
len et al. 2012). Here we took advantage of this finding to
perform control experiments showing the specificity of the
PLA technique. HEK-293T cells transiently expressing
CB1R, CB2R or both receptors were processed using the
PLA technique. As expected, CB1R–CB2R heteromers were
only identified in HEK-293T cells co-transfected with both
receptors, whereas cells containing only CB1Rs or CB2Rs
always lacked a positive PLA product (Fig. 6a, b, c). Fur-
thermore, the presence of molecular interactions within
CB1R–CB2R heteromers was confirmed by BRET mea-
surements taken from co-transfected HEK-293T cells. As
shown in Fig. 6d, the BRET signal increased as a hyper-
bolic function of the amount of CB1R–YFP expressed,
whereas the negative control made of CB1R–Rluc and
D4,2R-YFP resulted in a low and linear BRET saturation
curve.
Presence of CB1Rs, CB2Rs and CB1R–CB2R
heteromers in pallidothalamic neurons
Using a modified version of the PLA protocol the presence
of CB1Rs or CB2Rs was assessed within CTB-labeled
pallidothalamic projection neurons (Fig. 7). Obtained
results showed that both cannabinoid receptors are
expressed in pallidothalamic neurons and a qualitative
analysis of the expression levels for either CB1Rs or CB2Rs
showed a marked decline in both receptors in dyskinetic
animals, in keeping with what was observed at the mRNA
level. These results demonstrate that CB1R and CB2R
mRNA transcripts observed with in situ hybridization are
ultimately translated into related proteins and similar
qualitative changes in mRNA and protein levels were
observed in dyskinetic animals. The results also showed
that the receptors were located in the cellular somata of
projection neurons. Upon demonstrating that the two
receptors were indeed synthesized, determining the pre-
sence of heteromer expression was the next logical step.
We showed that CB1R–CB2R heteromers are present in
pallidothalamic projection neurons (Fig. 8). Qualitative
analysis of the relative levels of CB1R–CB2R heteromers in
these neurons revealed that, while there were no discern-
able differences between control and parkinsonian mon-
keys, there was a marked reduction in dyskinetic monkeys
(Fig. 8). It is worth noting that this reduction in CB1R–
CB2R heteromers observed in dyskinetic monkeys with the
Fig. 5 Quantification of CB1R and CB2R mRNA expression levels in
control, parkinsonian and dyskinetic monkeys. Histograms show the
mean values of the expression levels for each transcript of interest
across the experimental groups analyzed. Densitometries were carried
out at the single-cell level by counting the number of pixels per lm2
within a given region of interest (ROI). Measurements were taken
from a minimum of 80 neurons per monkey. Differences in CB1R
mRNA expression levels were statistically significant between control
and MPTP-treated animals (p = 0.021), control and dyskinetic
monkeys (p \ 0.001) and MPTP-treated and dyskinetic (p \ 0.001).
The mean difference values for CB2R mRNA were statistically
significant between control and dyskinetic animals (p \ 0.001) and
between MPTP and dyskinetic groups (p \ 0.001). Differences in
CB2R mRNA expression levels between control and MPTP-treated
monkeys were not significant (n.s., p = 0.946)
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PLA technique mimics the marked decrease in CB1R and
CB2R mRNA expression levels observed using dual fluo-
rescent in situ hybridization assays. Moreover, most of the
CB1Rs, CB2Rs and CB1R–CB2R heteromers were
observed in subcellular locations instead of in the plasma
membrane (Figs. 7, 8). This is in keeping with the earlier
reports providing ultrastructural evidence on the presence
of CB1Rs in somatodendritic compartments of rat striatal
neurons (Rodrı´guez et al. 2001) as well as in putative
GABAergic interneurons of the monkey prefrontal cortex
(Eggan and Lewis 2007). Indeed, Leterrier et al. (2006)
reported that approximately 30 % of CB1Rs were located
in endosomes, 50 % in intracellular, nonendosomal loca-
tions and only between 10 and 20 % of receptors were
observed in the plasma membrane. These data were
corroborated here following the ultrastructural detection of
PLA-stained material for CB1R–CB2R heteromers. The
study of GPe sections showed the presence of CB1R–CB2R
heteromers in both pre- and postsynaptic membranes of
symmetric synapses (Fig. 9a, a’). Meanwhile, the study of
GPi sections showed the presence of CB1R–CB2R hetero-
mers mainly in postsynaptic locations and the lack of in-
munoreactivity for CB1R–CB2R heteromers in axon
terminals, those comprising both symmetric and asym-
metric synapses (Fig. 9b, b’).
Discussion
Technical considerations
Here we demonstrate the co-expression of CB1R and CB2R
mRNA transcripts within pallidothalamic-projecting neu-
rons in the monkey, and provide quantitative measurements
of the changes in mRNA expression levels across different
clinical conditions. The main caveat of measuring levels of
mRNA transcripts is that they may not always correlate with
receptor protein levels (Sossin and DesGroseillers 2006).
Previous studies have shown, however, that differences in
CB1R mRNA expression levels are matched by differences
in CB1R immunoreactivity and CB1R ligand binding (Her-
kenham et al. 1991a, b; Mailleux and Vanderhaeghen 1992;
Egertova´ and Elphick 2000; Julian et al. 2003). Functionally,
it has been demonstrated that developmental changes in
bFig. 6 Detection of CB1–CB2 receptor heteromers in HEK-transfec-
ted cells. The specificity of the in situ proximity ligation assay (PLA)
was tested using HEK-293T cell lines transiently transfected with the
cDNAs of CB1R and CB2R (a, a’), with CB1R only (b, b’) or with
CB2R only (c, c’). Cells were processed for PLA stain according to
the guidelines issued by the manufacturer. Only when the two
receptors were present and in close proximity were CB1R–CB2R
heteromers detected as a punctuate fluorescent signal by confocal
microscopy. Since receptors are recognized by primary antibodies
linked to different DNA chains (a plus and a minus), CB1R–CB2R
receptor heteromers were only detected in HEK cells transfected with
both cDNAs but not in cells transfected only with either CB1 or CB2
cDNAs. Scale bar is 20 lm for panels a, b and c, and 5 lm for insets.
d BRET saturation experiments showing CB1R–CB2R heteromeriza-
tion were performed using cells transfected with 1 lg of cDNA
corresponding to CB1R–Rluc and increasing amounts of cDNA
(0–3 lg cDNA) corresponding to CB2R-YFP (triangles). As a
negative control, cells were also transfected with cDNA correspond-
ing to CB1R–Rluc (1 lg) and to D4,2R–YFP (0–4 lg cDNA)
(squares). Both fluorescence and luminescence for each sample was
measured before every experiment to confirm similar donor expres-
sions (approximately 100,000 bioluminescence units) while monitor-
ing the increase in acceptor expression (100–70,000 net fluorescence
units). The relative amount of BRET is given as the ratio between the
net fluorescence of the acceptor (YFP) and the luciferase activity of
the donor (Rluc). BRET data are expressed as mean ± s.e.m. of 4–8
different experiments grouped as a function of the amount of BRET
acceptor
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Fig. 7 Presence of CB1Rs and
CB2Rs in pallidothalamic-
projecting neurons of control,
parkinsonian and dyskinetic
monkeys. A modified version of
the PLA technique enabled the
visualization of single
cannabinoid receptors (red dots)
within CTB-labeled
pallidothalamic projection
neurons (green marker). Panels
a–c show CB1Rs in pallidal
efferent neurons of control (a),
MPTP-treated (b) and
dyskinetic (c) monkeys. Panels
d, e illustrate CB2Rs in pallidal
efferent neurons of control (d),
MPTP treated (e) and dyskinetic
(f) monkeys. The number of
both types of receptors was
clearly reduced in the dyskinetic
state. Scale bar is 10 lm in all
panels
Fig. 8 CB1R–CB2R heteromers
in pallidothalamic-projecting
neurons of control, parkinsonian
and dyskinetic monkeys.
Illustrative examples of
identified projection neurons
(CTB-labeled; green) taken
from control (a–c), MPTP-
treated (d–f) and dyskinetic
(g–i) monkeys. Each red dot
represents one CB1R–CB2R
receptor heteromer. Scale bar is
10 lm in all panels
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postsynaptic suppression of excitation in pyramidal neurons
of the prefrontal cortex are CB1R-mediated and these vari-
ations are paralleled by changes in CB1R mRNA levels
(Heng et al. 2011).
Another matter of concern is represented by the fact that
commercially available cannabinoid receptor antibodies
are not all created equal (Grimsey et al. 2008). In brief,
antibodies for CB1R are made against either the N-terminal
or the C-terminal and it is clear that a single antibody is
unlikely to detect all receptor species. Indeed, antibodies
directed towards different regions of CB1R may be
expected to yield different staining patterns. Here we used
a CB1R antibody directed against the N-terminal (from
Thermo Scientific), according with earlier descriptions
dealing with CB1R distribution in the primate brain (Ong
and Mackie 1999; Eggan and Lewis 2007). At the level of
the GPi nucleus, Ong and Mackie (1999) reported the
presence of scattered large diameter neurons, together with
very few immunoreactive fibers in the neutrophil, results
that are very much in keeping with those reported
here. Furthermore, it is also worth noting that extensive
CB1R immunoreactivity was described in GABAergic
striatopallidal boutons in rodents (Ma´tya´s et al. 2006). In
this regard, comparing the globus pallidus in rodent and
primates is often a source of misinterpretations, since the
rodent globus pallidus makes reference to the lateral globus
pallidus (LGP; external pallidus in monkeys, GPe),
whereas the rodent equivalent to the internal division of the
globus pallidus (GPi) in monkeys is represented both by
the entopeduncular nucleus (ENT) and the substantia nigra
pars reticulata (SNr). Because the ENT nucleus is made up
of a very few number of neurons intermingled within the
fiber bundles of the internal capsule, the SNr is considered
as the main basal ganglia output nucleus in rodents. In
other words and for comparison purposes, the globus pal-
lidus in rodents is the equivalent structure to the primate
GPe, and the same applies to the rodent SNr and the pri-
mate GPi. In this regard, the presence of CB1R immuno-
staining was mainly found in striatopallidal terminals
reaching the globus pallidus in rodents, whereas in the SNr
the majority of axon terminals forming symmetrical syn-
apses were CB1R negative (Ma´tya´s et al. 2006). In an
attempt to clarify this issue, we have tested a different anti-
CB1R antibody (directed towards the C terminus of the
receptor, known as the ‘‘Watanabe’s antibody’’ and pur-
chased from Frontiers Science, Japan). Using this antibody
in the monkey brain resulted in intense GPi neuropil
labeling. When compared with the nicely stained fibers and
terminals observed in the cerebral cortex and hippocampal
formation, the GPi stain is diffuse and therefore not enough
accurate to properly disclose CB1R-labeled fibers and ter-
minals (data not shown).
PLA results constitute the first description of CB1R–
CB2R heteromers in pallidothalamic projection neurons in
the monkey. The correlation between mRNA levels and the
amount of CB1R–CB2R heteromers detected by PLA sug-
gest that mRNAs for cannabinoid receptors in GPi neurons
are readily translated into protein. Although data gathered
from the PLA assays were merely qualitative, observed
changes fit with the data obtained from in situ hybridization
experiments. It is worth noting that it is not technically
possible to provide data on total CB1R or CB2R levels in
natural tissues and therefore we could not address whether
receptor heteromers were the only cannabinoid signaling
unit. Experiments carried out in rodents have shown that
CB2Rs may downregulate CB1R-mediated signaling when
forming heteromers with CB1Rs (Callen et al. 2012).
Indeed, a shift from CB1R to CB1R–CB2R signaling could
have significant functional implications. In other words, the
transcribed mRNA gives rise to monomers/homomers and
to heteromers. Although the total number of CB1Rs and
CB2Rs could be estimated using total membrane prepara-
tions of GPi homogenates, it should be noted that data
gathered from this technique do not necessarily reflect the
level of receptors on the cell surface, which is the place
Fig. 9 Ultrastructural localization of CB1R–CB2R heteromers in the
GPe (a, a’) and GPi (b, b’) nuclei using the PLA technique. a, a’
Electron micrograph showing CB1R–CB2R heteromers located in the
pre- (Ax) and postsynaptic elements (d) in GPe. (a’) Inset taken from
(a) at higher magnification showing that cannabinoid receptor
heteromers are found in both the pre- and postsynaptic membranes
in a symmetric synapse (arrow). b, b’ At the level of the GPi nucleus,
cannabinoid receptor heteromers are confined to postsynaptic loca-
tions (d). (b’) Inset taken from (b) at higher magnification showing a
GPi dendrite (d) simultaneously receiving one symmetrical (arrow)
and one asymmetrical synapses (arrowhead). Scale bar is 500 nm for
panels a and b, and 200 nm for insets a’ and b’
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where endocannabinoids mainly interact with their related
receptors. Moreover, receptor quantification by means of
radioligand binding competition assays may not result in
fully reliable data as the affinity constants vary when a
given receptor is forming different heteromers when
comparing control versus ‘‘diseased’’ animal models. The
proportion of receptors forming or not heteromers at any
given time is dynamic and may change in response to
activity or pathological states (Gonzalez et al. 2012). The
combination of mRNA and heteromer detection across all
experimental groups supports this idea and, interestingly,
whereas no noticeable difference in the number of CB1Rs,
CB2Rs and CB1R–CB2R heteromers was found between
control and parkinsonian monkeys, a marked decreased
was noticed in dyskinetic monkeys.
Presence of cannabinoid receptors and receptor
heteromers in pallidothalamic neurons
Data gathered using in situ hybridization cannot provide
information about pre- or postsynaptic distribution of
CB1Rs and CB2Rs. These receptors may be transported
anterogradely to distal axon terminals (presynaptic distri-
bution), remain in close vicinity to the place of synthesis to
be incorporated in the plasma membrane in cell somata and
dendrites (postsynaptic distribution), or a combination of
the two. Results obtained with the PLA technique do pro-
vide, however, information concerning the distribution of
cannabinoid receptors in the GPi. Here, CB1Rs, CB2Rs and
CB1R–CB2R heteromer complexes were identified in the
cell bodies of pallidothalamic projection neurons (CTB-
labeled).
Obtained data were also confirmed using electron
microscopy, describing for the first time CB1R–CB2R
heteromers in primate GPi. Our results showed the pre-
sence of heteromers in postsynaptic elements in the GPi.
For comparison purposes, the GPe was also studied, where
we have found a different inmunoreactive pattern: unlike in
the GPi, at the GPe level CB1R–CB2R heteromers are
mainly found in both pre- and postsynaptic membranes.
Previous studies in other cerebral areas in mouse, rat,
monkeys or humans have shown that CB1Rs are mainly
present in the presynaptic elements (Katona et al. 1999,
2000; Eggan and Lewis 2007; Ma´tya´s et al. 2006; La-
fourcade et al. 2007; Chiu et al. 2010; Puente et al. 2010;
Reguero et al. 2011) while other studies had describe the
presence of CB1R in pre- and postsynaptic elements, even
located in neuronal somas (Ong and Mackie 1999; Rodrı´-
guez et al. 2001; Pickel et al. 2004; Wilson-Poe et al.
2012). Since the presence of CB1R–CB2R heteromers in
GPi in primates was not previously described, we con-
sider that the absence of those heteromers in the presyn-
aptic element is plausible. Regarding methodological
considerations at the ultrastructural level, we have con-
sidered inmunoreactive CB1R–CB2R profiles when even
only one gold particle was present, since the background
labeling was minimal and in keeping with earlier studies
showing that even one gold particle in small profiles can
represent an important density of labeling (Wang and
Pickel 2002; Pickel et al. 2004). Gold silver labeling
method shows a lower relatively sensitivity than the per-
oxidase method, however gold-silver labeling does permit
a more precise subcellular localization of inmunoreactivity.
Endocannabinoids activate CB1Rs via a retrograde sig-
naling process in which the compounds are released from
postsynaptic neuronal elements, travelling back to the
presynaptic terminal to act on pre- and perisynaptic
receptors. This mechanism has been implicated in short-
term synaptic depression, including suppression of excit-
atory or inhibitory transmission (see Lovinger 2008, for
review). A relevant question is why the two cannabinoid
receptors subtypes are co-expressed in the same projection
neurons. Both receptors are G-protein-coupled receptors
(GPCRs) linked to Gi/o proteins (Bayewitch et al. 1995;
Gonsiorek et al. 2000; Shoemaker et al. 2005), i.e. nega-
tively coupled to adenylyl cyclase (Demuth and Molleman
2006). Further, the endocannabinoid 2-arachidonoylglyc-
erol is a full endogenous agonist of both CB1Rs and
CB2Rs, although CB2Rs have a higher sensitivity to this
molecule (Atwood et al. 2012). While the two receptors
behave similarly from a pharmacological point of view,
receptor heteromerization suggest a postsynaptic signaling
unit constituted by the heteromer that likely conveys a
specific signal in pallidothalamic neurons. It is already
accepted that GPCR heteromers are functionally distinct
units and not a mere assembly of two receptors with
independent functions (Ferre´ et al. 2009). Similar examples
of heteromers for the same subfamily include opioid
(Constantino et al. 2012), dopamine (Hasbi et al. 2009;
Perreault et al. 2012) and adenosine (Ciruela et al. 2006)
receptors, among others (reviewed in Hiller et al. 2013).
The role of CB1R–CB2R heteromers in basal ganglia out-
put signal modulation is a matter of speculation but the
prediction would be that some of the conflicting data on
comparing in vitro cell pharmacology with behavioral
responses to endocannabinoids or to synthetic ligands
could be attributed to the occurrence of CB1R–CB2R het-
eromers in pallidothalamic neurons.
Cannabinoid receptors in the parkinsonian state
Increases in CB1R mRNA expression levels (Mailleux and
Vanderhaeghen 1993; Romero et al. 2000), and in CB1R
ligand binding (Lastres-Becker et al. 2001) have been
reported in parkinsonian animals. An increase in presyn-
aptic CB1R levels in corticostriatal neurons would lead to a
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reduction in glutamate release (Gerdeman and Lovinger
2001; Brown et al. 2003), possibly representing a com-
pensatory mechanism. The present study shows a slight
increase in CB1R mRNA transcripts within GPi neurons of
MPTP-treated monkeys. CB1Rs may be transported
through GABAergic terminals to the thalamus to reduce
GABA release in an attempt to decrease over-inhibition of
the thalamus. Alternatively, this modest increase could
simply be a secondary effect to the increase in subthalamic
glutamatergic afferents to GPi, whereby an increase in
glutamatergic receptor activation can stimulate an increase
in CB1R mRNA synthesis (Mailleux and Vanderhaeghen
1994). However this possibility would not fit with the
subcellular localization of the receptors in pallidothalamic
neurons. Moreover, ultrastructural evidence of CB1Rs
located in the somatodendritic compartment of striatal
neurons in rats has been reported elsewhere (Rodrı´guez
et al. 2001). Indeed, there are also available evidences
showing that CB1Rs are associated to the Golgi apparatus
and rough endoplasmic reticulum within GABAergic
interneurons of the macaque prefrontal cortex (Eggan and
Lewis 2007). In this regard, Leterrier et al. (2006) reported
that approximately 30 % of CB1Rs are located in subcel-
lular endosomal compartment and only between 10 and
20 % on the plasma membrane, the rest being intracellular,
nonendosomal receptors. Concerning CB2Rs, the results
reported here cannot be compared with other in the liter-
ature due to the lack of data describing expression levels in
parkinsonian states. Further experiments will be required to
properly assess the subcellular localization of CB1Rs,
CB2Rs and CB1R–CB2R heteromers, as well as the
potential changes in receptor distribution following dif-
ferent experimental conditions. Upregulation of CB2Rs in
conditions of striatal degeneration in glial cells has been
described in Huntington’s disease (Sagredo et al. 2009),
however it is not yet clear whether CB2Rs are upregulated
in glial cells in response to neuronal damage in PD
(reviewed in Fernandez-Ruiz et al. 2007, 2008). The small
increase in CB1R mRNA in parkinsonian macaques did not
translate into a higher quantity of CB1R–CB2R heteromers,
suggesting that either CB2Rs are a limiting factor in the
formation of these heteromers or that the increase in CB1Rs
was not sufficient to significantly affect the number of
CB1R–CB2R heteromers formed.
Cannabinoid receptors in the dyskinetic state
With regard to data from dyskinetic animals, both CB1R
and CB2R mRNAs synthesized in the GPi decreased with
respect to the levels found in control and parkinsonian
monkeys. A marked decrease in CB1Rs, CB2Rs and CB1R–
CB2R heteromers was also found. These changes in
expression levels and heteromer formation may be com-
pensatory in an attempt to reverse increased neuronal
activity to a state of normality. A decrease in CB1Rs and/or
CB2Rs located on pallidothalamic neurons may lower the
threshold for firing underactive GPi neurons by glutamate
released from the subthalamic nucleus.
There is evidence for a downregulation of CB1Rs in the
early stages or presymptomatic states of PD (Garcia-
Arencibia et al. 2009) and the dyskinetic state may emulate
this phenomenon. Although one study did find an increase
in CB1R mRNA levels in the striatum in 6-OHDA lesioned
rats chronically treated with levodopa (Zeng et al. 1999),
levodopa has since then been found to consistently reverse
both the elevation of endocannabinoid levels (Maccarrone
et al. 2003; van der Stelt et al. 2005) and the PD-related
increase in CB1R density and binding (Lastres-Becker et al.
2001). Both CB1R agonists (Ferrer et al. 2003; Gilgun-
Sherki et al. 2003; Segovia et al. 2003; Fernandez-Ruiz
et al. 2007; Morgese et al. 2007, 2009) and antagonists
(Segovia et al. 2003; van der Stelt et al. 2005) show anti-
dyskinetic activity in MPTP-treated primates and 6-OHDA
lesioned rats. This apparent paradox may result from the
presence of CB1Rs in both excitatory and inhibitory syn-
apses within basal ganglia circuits and/or from the pre- and
postsynaptic expression of CB1R-containing heteromers.
Finally, it is worth noting that a recent study on GPCR
heteromers made of adenosine 2A, CB1 and dopamine D2
receptors in macaques also showed that the chronic treat-
ment with levodopa disrupts all these types of heteromers
at the level of the caudate nucleus (Bonaventura et al.
2014).
Concluding remarks
The presence of CB1R–CB2R heteromers in pallidotha-
lamic neurons adds a new dimension to their role in
basal ganglia function. Determining the precise function
of CB1R–CB2R heteromers and elucidating the way in
which these receptors modify neuronal signaling in the
GPi will pave the way for the discovery of specific
drugs that may either reduce GPi overactivity in the
parkinsonian state or provide more effective management
of dyskinesia.
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